By
Cena:People pass a test in regenerating liver that works in animals The Spanish Agency for Medicines and Health Products has authorized the biotechnology company Digna Biotech start the first clinical trial with people, Phase I, cardiotrophin-I (CT-I), a molecule that stimulates liver regeneration in animal models. The Center for Applied Medical Research (CIMA), University of Navarre has patented the molecule "for its ability to stimulate liver regeneration after partial removal in animal models, as well as protect the liver against ischemia-reperfusion injury." It also "prevents cell death during acute liver failure," as reported in a statement CIMA, which has indicated that the first trial was held in the University Hospital of Navarra and the Hospital Universitario Puerta de Hierro in Madrid and will include 33 healthy volunteers. CIMA has the rights to intellectual property for the use of CT-I in the treatment of certain liver diseases. Its preclinical development "has been made possible by financial support from ClaveSuan biomedical development of the Center for Industrial Technological Development (CDTI) and the Government of Navarra," added these sources. People pass a test in regenerating liver that works in animals The European Medicines Agency and the Food and Drug Administration United States have given to the CT-I protein orphan drug designation to prevent ischemia-reperfusion injury associated with solid organ transplantation. They are known as orphan who, being of interest to the health of the population, are not developed by the pharmaceutical industry due to low profitability, and that target a very small group of patients. In addition, the FDA has given the CT-I orphan drug designation for the liver transplant.
Source: Forum Human Health,
Image
